Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.
2.

Focus on paroxetine.

Green B.

Curr Med Res Opin. 2003;19(1):13-21. Review.

PMID:
12661775
3.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
4.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
5.

Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.

Zajecka J, Tracy KA, Mitchell S.

J Clin Psychiatry. 1997 Jul;58(7):291-7. Review.

PMID:
9269249
6.

Agomelatine treatment of major depressive disorder.

Dolder CR, Nelson M, Snider M.

Ann Pharmacother. 2008 Dec;42(12):1822-31. doi: 10.1345/aph.1L296. Epub 2008 Nov 25. Review.

PMID:
19033480
7.

The effects of agomelatine on sexual function in depressed patients and healthy volunteers.

Montejo A, Majadas S, Rizvi SJ, Kennedy SH.

Hum Psychopharmacol. 2011 Dec;26(8):537-42. doi: 10.1002/hup.1243. Epub 2011 Nov 21. Review.

PMID:
22102540
8.

Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

San L, Arranz B.

Eur Psychiatry. 2008 Sep;23(6):396-402. doi: 10.1016/j.eurpsy.2008.04.002. Epub 2008 Jun 25. Review.

PMID:
18583104
9.

Clinical management of antidepressant discontinuation.

Rosenbaum JF, Zajecka J.

J Clin Psychiatry. 1997;58 Suppl 7:37-40. Review.

PMID:
9219493
10.

Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Black K, Shea C, Dursun S, Kutcher S.

J Psychiatry Neurosci. 2000 May;25(3):255-61. Review.

11.

Discontinuation symptoms in depression and anxiety disorders.

Baldwin DS, Montgomery SA, Nil R, Lader M.

Int J Neuropsychopharmacol. 2007 Feb;10(1):73-84. Epub 2005 Dec 19. Review.

PMID:
16359583
12.

The use of antidepressants in clinical practice: focus on agomelatine.

McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S.

Hum Psychopharmacol. 2010 Mar;25(2):95-102. doi: 10.1002/hup.1094. Review.

PMID:
20196187
13.

Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel.

Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J.

J Clin Psychiatry. 1997;58 Suppl 7:23-7. Review.

PMID:
9219490
14.

A review of preliminary observations on agomelatine in the treatment of anxiety disorders.

Levitan MN, Papelbaum M, Nardi AE.

Exp Clin Psychopharmacol. 2012 Dec;20(6):504-9. doi: 10.1037/a0030263. Epub 2012 Oct 22. Review.

PMID:
23088208
15.

Focus on agomelatine.

Green B.

Curr Med Res Opin. 2011 Apr;27(4):745-9. doi: 10.1185/03007995.2011.554534. Epub 2011 Jan 27. Review.

PMID:
21271795
16.

Chronic paroxetine treatment: effects on other non-serotonergic neurotransmitter systems.

Ballesteros-Zebadua P, Manjarrez-Marmolejo J, Franco-Perez J.

CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1226-32. Review.

PMID:
24138712
17.

SSRI discontinuation syndrome. Awareness as an approach to prevention.

Ditto KE.

Postgrad Med. 2003 Aug;114(2):79-84. Review.

PMID:
12926179
18.

Agomelatine: an agent against anhedonia and abulia?

Thome J, Foley P.

J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S3-7. doi: 10.1007/s00702-013-1126-6. Epub 2013 Dec 6. Review.

PMID:
24311062

Supplemental Content

Support Center